IP Watch on January 25 published GlaxoSmithKline’s position statement on the Anti-Counterfeiting Trade Agreement. The company generally supports the agreement, as it “fully supports any efforts aimed at ensuring strong enforcement of IPRs.” GSK would have preferred to have seen the inclusion of patents in the civil enforcement, but it has “no objection to the omission of criminal sanctions for patent infringers” and “no objection to the exclusion of in-transit patent provisions.”
Click here for the full Position Statment
QUT Media4th November 2025 The United Kingdom Parliament is considering a bill aimed at making smoking obsolete, which has been
Speaking at the Global Expert Network on Copyright User Rights Symposium on 16 June 2025, Professor Christophe Geiger argues for
On 25 September 2025, Professor Wend Wendland, delivered the 14th Peter Jaszi Distinguished Lecture at American University in Washington D.C..
On September 18, 2025, the Italian Senate definitively approved the country’s first comprehensive framework law on artificial intelligence (AI). The
Por Andrés Izquierdo Durante la segunda semana de agosto, fui invitado a hablar en la Feria Internacional del Libro de
By Andrés Izquierdo AI, Copyright, and the Future of Creativity: Notes from the Panama International Book FairDuring the second week